Here’s What Pushed Crispr Therapeutics AG Up 23.6% in December – nwitimes.com
nwitimes.com |
Here’s What Pushed Crispr Therapeutics AG Up 23.6% in December
nwitimes.com Shares of Crispr Therapeutics AG (NASDAQ: CRSP), a biotech start-up named after the promising new gene-editing technology it’s focused on, bounded 23.6% higher in December, according to data from S&P Global Market Intelligence. A new collaboration deal … CRISPR Therapeutics Announces Proposed Public Offering of …GlobeNewswire (press release) A Comparison of Top Movers: Overstock.com, Inc. (OSTK), CRISPR Therapeutics AG (CRSP)StockNewsGazette Head-To-Head Contrast: Crispr Therapeutics (CRSP) vs. Incyte (INCY)Dispatch Tribunal The Lincolnian Online –The Ledger Gazette all 31 news articles » |
CNA Finance (press release) |
Cellect Announces Stem Cell Triumph
Nasdaq (RTTNews.com) – The shares of Cellect Biotechnology Ltd. ( APOP ) surged in the pre-market as it unveiled the stem cell technology breakthrough with hundred percent acceptance. Thursday, the company said its ApoGraft Stem Cell transplant has zero … Cellect Bio’s ApoGraft stem cells completely accepted by first blood cancer patients in Phase 1/2 study; shares up …Seeking Alpha Cellect (APOP) Says First Group of Patients in Clinical Trial With its ApoGraft Stem Cell Transplant Follow up …StreetInsider.com Cellect Biotechnology (APOP) Stock: Gaining On Stem Cell BreakthroughCNA Finance (press release) ForexTV.com all 11 news articles » |
Dispatch Tribunal |
Here’s What Pushed Crispr Therapeutics AG Up 23.6% in December
Motley Fool Shares of Crispr Therapeutics AG (NASDAQ:CRSP), a biotech start-up named after the promising new gene-editing technology it’s focused on, bounded 23.6% higher in December, according to data from S&P Global Market Intelligence. A new collaboration deal … CRISPR Therapeutics Announces Proposed Public Offering of …GlobeNewswire (press release) A Comparison of Top Movers: Overstock.com, Inc. (OSTK), CRISPR Therapeutics AG (CRSP)StockNewsGazette Crispr Therapeutics (CRSP) Lifted to “Buy” at BidaskClubStockNewsTimes Dispatch Tribunal –Simply Wall St –The Ledger Gazette all 31 news articles » |
|
Atlas-backed Generation Bio promises ‘druglike’ gene therapy
FierceBiotech Backed by Atlas Ventures with a $25 million series A and headed by ex-Sobi CEO Geoff McDonough, Generation Bio says its lipid nanoparticle platform will allow it to offer the first genetic medicines that can be titrated to a particular dose—and … |